ÁßÁõ ÆÐÇ÷Áõ ¹× ÆÐÇ÷¼îÅ© ȯÀÚµéÀÇ 28Àϰ »ç¸Á ¿¹Ãø ÀÎÀڷμ­ ¹Ì¼º¼÷ °ú¸³±¸ÀÇ Æò°¡
Validation of Immature Granulocyte as a Predictor for the 28-Day Mortality in Patients with Severe Sepsis and Septic Shock

´ëÇÑÀÀ±ÞÀÇÇÐȸÁö 2014³â 25±Ç 2È£ p.167 ~ p.173

°í¿µ»ó(Ko Young-Sang) - ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÀÀ±ÞÀÇÇб³½Ç
ÇÏ»ó¿í(Ha Sang-Ook) - ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÀÀ±ÞÀÇÇб³½Ç
Á¤·çºñ(Jeong Ru-Bi) - ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÀÀ±ÞÀÇÇб³½Ç
ÃÖº´È£(Choi Byung-Ho) - ¿ï»ê´ëÇб³ Àǰú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÀÀ±ÞÀÇÇб³½Ç

Abstract

Purpose: Recently, several studies for immature granulocyte proportion (IG%) in patients with sepsis have revealed its association with diagnosis and prognosis of patients with sepsis. In this study, we enrolled patients with severe sepsis and septic shock and compared IG% with other biologic markers as a predictor of 28-day mortality.

Methods: This was a retrospective study for patients with severe sepsis and septic shock who were admitted to the emergency department of a tertiary care hospital for fourmonths. The IG% measured using Sysmex XE-2100 and other inflammatory markers, including C-reactive protein, lactate, and procalcitonin were evaluated and compared for 28-day mortality.

Results: A total of 85 patients with septic shock and 45 patients with severe sepsis were enrolled. In the non-survivors group (n=32, 24.6%), APACHE II score (p=0.017), use of continuous renal replacement therapy (CRRT) (p=0.002), and septic shock (p=0.009) were statistically higher compared with thesurvivors group. APACHE 2 score (Odd ratio [OR] 1.099, p=0.008) and IG% (¡Ã0.5%) (OR 3.568, p=0.036) predicted the 28-day mortality independently after adjusting SOFA score, septic shock, disseminated intravascular coagulopathy, use of CRRT, and gender. However, IG (¡Ã0.5%) had low specificity of 33.7% and positive predictive value (PPV) of 30.1% for 28-day mortality.

Conclusion: IG% could be a useful biologic marker for prediction of 28-day mortality in patients with severe sepsis or septic shock. However, the limitation of low specificity and PPV must be considered in clinical use.

Ű¿öµå

Biologic markers, Granulocytes, Mortality, Sepsis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå